JP2013545757A - 癌の治療方法 - Google Patents

癌の治療方法 Download PDF

Info

Publication number
JP2013545757A
JP2013545757A JP2013539999A JP2013539999A JP2013545757A JP 2013545757 A JP2013545757 A JP 2013545757A JP 2013539999 A JP2013539999 A JP 2013539999A JP 2013539999 A JP2013539999 A JP 2013539999A JP 2013545757 A JP2013545757 A JP 2013545757A
Authority
JP
Japan
Prior art keywords
amino acid
acid change
mutation
cancer
causing amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013539999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545757A5 (enExample
Inventor
トナ、エム．ギルマー
ピーター、エフ．ルボウィッツ
リ、リウ
ジョリー、マズムダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2013545757A publication Critical patent/JP2013545757A/ja
Publication of JP2013545757A5 publication Critical patent/JP2013545757A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2013539999A 2010-11-17 2011-11-17 癌の治療方法 Pending JP2013545757A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41452110P 2010-11-17 2010-11-17
US61/414,521 2010-11-17
PCT/US2011/061135 WO2012068339A2 (en) 2010-11-17 2011-11-17 Methods of treating cancer

Publications (2)

Publication Number Publication Date
JP2013545757A true JP2013545757A (ja) 2013-12-26
JP2013545757A5 JP2013545757A5 (enExample) 2015-01-08

Family

ID=46084636

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013539999A Pending JP2013545757A (ja) 2010-11-17 2011-11-17 癌の治療方法

Country Status (4)

Country Link
US (1) US20130231346A1 (enExample)
EP (1) EP2640390A4 (enExample)
JP (1) JP2013545757A (enExample)
WO (1) WO2012068339A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2900301T3 (es) 2013-03-15 2022-03-16 Novartis Ag Biomarcadores asociados con la inhibición de BRM
WO2015005473A1 (ja) * 2013-07-12 2015-01-15 独立行政法人国立がん研究センター がんの治療への応答性を予測する方法
EP3074019A1 (en) * 2013-11-27 2016-10-05 Oncoethix GmbH Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds
WO2015164743A2 (en) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
WO2016176338A1 (en) * 2015-04-30 2016-11-03 The Trustees Of Columbia University In The City Of New York Small molecule ras ligands
CA2996513A1 (en) * 2015-08-25 2018-03-02 President And Fellows Of Harvard College Methods and compositions relating to the diagnosis and treatment of cancer
US12246067B2 (en) 2018-06-19 2025-03-11 Biontech Us Inc. Neoantigens and uses thereof
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN116355851B (zh) * 2023-03-13 2023-09-08 广州医科大学附属第一医院（广州呼吸中心） 一种来源于人非小细胞肺癌的原代细胞株及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501631A (ja) * 2004-06-11 2008-01-24 日本たばこ産業株式会社 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
WO2010006225A1 (en) * 2008-07-11 2010-01-14 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
JP2010532756A (ja) * 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
JP2013511525A (ja) * 2009-11-17 2013-04-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
KR20080108517A (ko) * 2006-04-05 2008-12-15 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
MX2010012064A (es) * 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
WO2012061683A2 (en) * 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501631A (ja) * 2004-06-11 2008-01-24 日本たばこ産業株式会社 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
JP2010532756A (ja) * 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
WO2010006225A1 (en) * 2008-07-11 2010-01-14 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
JP2013511525A (ja) * 2009-11-17 2013-04-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6014051273; Ｎａｔ　Ｍｅｄ Ｖｏｌ．１４，　Ｎｏ．１２, 2008, ｐ．１３５１-１３５６ *
JPN6015037193; Ｂｒｉｔｉｓｈ　ｊｏｕｒｎａｌ　ｏｆ　ｃａｎｃｅｒ Ｖｏｌ．１００，　Ｎｏ．２, 2009, ｐ．３７０-３７５ *
JPN6015037194; Ｃａｒｃｉｎｏｇｅｎｅｓｉｓ Ｖｏｌ．３０，　Ｎｏ．４, 2009, ｐ．５４７-５５４ *
JPN6015037195; Ｅｕｒｏｐｅａｎ　ｊｏｕｒｎａｌ　ｏｆ　ｃａｎｃｅｒ，　Ｓｕｐｐｌｅｍｅｎｔ Ｖｏｌ．６，　Ｉｓｓｕｅ　１２, 2008, ｐ１７８　［５６７］ *
JPN6015037196; Ｃａｎｃｅｒ　ｒｅｓｅａｒｃｈ Ｖｏｌ．６７，　Ｎｏ．２３, 2007, ｐ．１１３００-１１３０８ *
JPN7015002542; Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．７０，　Ｎｏ．８，　Ｓｕｐｐ．　１, 20100415, Ａｂｓｔｒａｃｔ　Ｎｕｍｂｅｒ：　３８５５ *

Also Published As

Publication number Publication date
US20130231346A1 (en) 2013-09-05
WO2012068339A2 (en) 2012-05-24
WO2012068339A3 (en) 2012-09-27
EP2640390A2 (en) 2013-09-25
EP2640390A4 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
JP2013545757A (ja) 癌の治療方法
US20130217710A1 (en) Methods for treating cancer
Dufresne et al. Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours
US9730925B2 (en) Methods of treating cancer
US20130231347A1 (en) Method of treatment with braf inhibitor
WO2012071321A1 (en) Method of treating cancer
US20140221372A1 (en) Method of administration and treatment
US20170105997A1 (en) Methods of treating cancer
EP3111222A1 (en) Methods of treating cancer patients responding to ezh2 inhibitor gsk126
Chang et al. RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients
AU2012275315B2 (en) Method of administration and treatment
WO2014093750A1 (en) Method of administration and treatment
JP5834370B2 (ja) 組合せ
JPWO2019039390A1 (ja) 若年性骨髄単球性白血病治療薬
WO2015059677A1 (en) Methods of treating cancer
JP2025507955A (ja) 癌の治療のための精密療法
US20220218694A1 (en) Crenolanib for treating flt3 mutated proliferative disorders associated mutations
Mazza New molecular drivers in NSCLC: The role of MET

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160223